Synthesis and Biological Evaluation of 8-Quinolinamines and Their Amino Acid Conjugates as Broad-Spectrum Anti-infectives

[Image: see text] In the search of therapeutic agents for emerging drug-resistant parasites, the synthesis of newer classes of 8-quinolinamines has emerged as a successful chemotherapeutic approach. We report synthesis of 8-quinolinamines bearing 5-alkoxy, 4-methyl, and 2-tert-butyl groups in the quinoline framework and their amino acid conjugates as broad-spectrum anti-infectives. 8-Quinolinamines exhibited potent in vitro antimalarial activity [IC(50) = 20–4760 ng/mL (drug-sensitive Plasmodium falciparum D6 strain) and IC(50) = 22–4760 ng/mL (drug-resistant P. falciparum W2 strain)]. The most promising analogues have cured all animals at 25 mg/kg/day against drug-sensitive Plasmodium berghei and at 50 mg/kg/day against multidrug-resistant Plasmodium yoelii nigeriensis infections in Swiss mice. The in vitro antileishmanial activities (IC(50) = 0.84–5.0 μg/mL and IC(90) = 1.95–7.0 μg/mL) comparable to standard drug pentamidine were exhibited by several of the synthesized 8-quinolinamines. At the same time, very promising antifungal activities (Candida albicans—IC(50) = 4.93–19.38 μg/mL; Candida glabrata—IC(50) = 3.96–19.22 μg/mL; Candida krusei—IC(50) = 2.89–18.95 μg/mL; Cryptococcus neoformans—IC(50) = 0.67–18.64 μg/mL; and Aspergillus fumigatus—IC(50) = 6.0–19.32 μg/mL) and antibacterial activities (Staphylococcus aureus—IC(50) = 1.33–18.9 μg/mL; methicillin-resistant S. aureus—IC(50) = 1.38–15.34 μg/mL; and Mycobacterium intracellulare—IC(50) = 3.12–20 μg/mL) were also observed. None of the 8-quinolinamines exhibited cytotoxicity and therefore are a promising structural class of compounds as antiparasitic and antimicrobials.